Lapatinib, which Garnier calls “an exquisitely designed drug” meant to treat tumors related to breast cancer, was originally put on a fast track by the FDA, and the company was expected to submit it for market approval this year. But Glaxo backtracked in May after receiving disappointing trial data. Now the drug may not be submitted for FDA approval until late this decade, according to some estimates.
http://www.financialexpress.com/fe_full_st...ontent_id=99139